Eisai highlights new Fycompa data at ECE 2014

Eisai has shared new data on its epilepsy drug Fycompa at the European Congress on Epileptology (ECE), which took place in Stockholm this week.

Information on the real-world performance of the approved perampanel-based therapy were published in ten abstracts during the event, as well as subset data from phase III pivotal trials.

The observational studies evaluated real-world experience with adjunctive perampanel in more than 350 refractory patients across sites in the UK and Austria, revealing the drug was well tolerated in a variety of populations, including those with highly refractory epilepsy and a large number of comorbidities.

Further findings suggested lipid parameters and glucose levels remained stable over time across a range of Fycompa doses.

Sten Friberg, Nordic medical director for Eisai Europe, said: "Data such as this adds to the growing weight of evidence that supports the use of perampanel for adults and adolescents with refractory epilepsy."

The drug is manufactured by Eisai in the UK and has been approved in Europe since July 2012.